Enlivex Pitches Longevity-Prediction Markets Hybrid Model to Institutional Investors
Event summary
- Enlivex is a Gold Sponsor of Proof of Talk 2026 in Paris, hosting a dinner for 40 institutional investors.
- CEO Oren Hershkovitz will present Enlivex's dual strategy: longevity therapeutics and prediction markets treasury.
- The event convenes leaders representing $18 trillion in assets under management.
- Enlivex combines Allocetra™ immunotherapy development with Rain Protocol-based prediction markets exposure.
The big picture
Enlivex is positioning itself at the intersection of two emerging markets: quality longevity therapeutics and institutional-grade prediction markets. The company's strategy reflects a broader trend of public companies integrating digital asset treasury strategies with core business operations. With $18 trillion in AUM represented at Proof of Talk, Enlivex's presentation could signal growing institutional interest in this hybrid model.
What we're watching
- Institutional Adoption
- How Enlivex's integrated model will attract institutional allocators to prediction markets.
- Regulatory Clarity
- Whether evolving regulations will support or hinder Enlivex's dual strategy.
- Market Integration
- The pace at which prediction markets become recognized capital infrastructure.
Related topics